Flow Medical closes $6M financing ahead of first-in-human evaluation
Sourced news brief · See the publication date above and original source below.
Chicago-based Flow Medical announced the close of a $6 million financing on November 2, including participation from multiple strategic medical-device investors. The University of Chicago spinout is developing the HELYX-PE system for catheter-directed treatment of pulmonary embolism.
The company says the financing will support first-in-human clinical evaluation, continued product development and manufacturing, and preparation for a U.S. pivotal study intended to support a future FDA submission.
Those milestones remain prospective. HELYX-PE is investigational and has not been cleared or approved by the U.S. Food and Drug Administration for commercial use. The useful follow-up evidence will be authorization and completion of the planned studies, documented safety and performance, and progress through the regulatory pathway—not the financing alone.
Browse Illinois startup and venture coverage and the Heartland newsroom.